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ABSTRACT
Background and Purpose The selection of the most suitable
animal species and subsequent translation of the concentration-
effect relationship to humans are critical steps for accurate assess-
ment of the pro-arrhythmic risk of candidate molecules. The
objective of this investigation was to assess quantitatively the dif-
ferences in the QTc prolonging effects of moxifloxacin between
cynomolgusmonkeys, dogs and humans. The impact of interspe-
cies differences is also illustrated for a new candidate molecule.
Experimental Approach Pharmacokinetic data and ECG
recordings from pre-clinical protocols in monkeys and dogs
and from a phase I trial in healthy subjects were identified
for the purpose of this analysis. A previously established Bayes-
ian model describing the combined effect of heart rate, circa-
dian variation and drug effect on the QT interval was used to
describe the pharmacokinetic-pharmacodynamic relation-
ships. The probability of a ≥10ms increase inQTwas derived
as measure of the pro-arrhythmic effect.
Key Results For moxifloxacin, the concentrations associated
with a 50% probability of QT prolongation ≥10 ms (Cp50)
varied from 20.3 to 6.4 and 2.6 μM in dogs, monkeys and
humans, respectively. For NCE05, these values were 0.4 μM
vs 2.0 μM for monkeys and humans, respectively.
Conclusions and Implications Our findings reveal significant
interspecies differences in the QT-prolonging effect of
moxifloxacin. In addition to the dissimilarity in pharma-
cokinetics across species, it is likely that differences in pharma-
codynamics also play an important role. It appears that,
regardless of the animal model used, a translation function is
needed to predict concentration-effect relationships in humans.
KEY WORDS cardiovascular safety . drug development .
interspecies differences . PKPDmodelling . QT interval
prolongation
ABBREVIATIONS
Cmax Peak drug concentration
Cp50 Concentration associated with a 50% probability of
QT interval prolongation ≥10 ms
ECG Electrocardiogram
EDTA Ethylenediaminetetraacetic acid
GLP Good laboratory practice
hERG Human Ether-à-go-go-Related Gene
HR Heart rate
LOQ Limit of quantification
PD Pharmacodynamic(s)
PK Pharmacokinetic(s)
PKPD Pharmacokinetic-pharmacodynamic
QTc Heart rate corrected QT interval
INTRODUCTION
The occurrence of pro-arrhythmic effects following adminis-
tration of non-antiarrhythmic drugs remains an important
cause of attrition in drug discovery and development.
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Currently, mitigation measures are in place which rely on the
assessment of QTc prolongation as a surrogate marker for the
risk of drug-inducedTorsades de pointes (1, 2). Compounds that
show any binding (affinity) and activity (inhibition) on hERG
mediated K+ current in pre-clinical investigations (3, 4) are
flagged and eventually discarded without clear understanding
of their effects on cardiac repolarisation at therapeutic or
supra-therapeutic concentrations in humans. Meanwhile, a
myriad of experimental protocols in vitro and in vivo is used for
screening and the evaluation of safety pharmacology, but little
information is available on which species and experimental
conditions bear clinical relevance. Specifically, most protocols
have not been validated in terms of their sensitivity, specificity
and predictive value. Moreover, limited attention is given to the
underlying concentration-exposure relationships (5, 6).
Differently from traditional empirical research, in drug de-
velopment pre-clinical in vitro and in vivo models are needed
that are predictive of QT prolongation in humans at thera-
peutic concentrations. This requires not only insight into the
intrinsic properties of a compound on the QTc interval per se
but also into the magnitude of interspecies differences.
Subsequently, accurate interpretation of such differences can
be made by using the concentration-effect relationships of the
compounds relative to the drug levels that are reached upon
the administration of therapeutic doses. In this respect it is
important to realise that drug-concentration-effect relation-
ships can differ significantly between species (7, 8)
Recently Holzgrefe et al. studied the interspecies differ-
ences in QTc effects across a wide range of commonly used
non-rodent species (9). Their analysis emphasised the elec-
trophysiological basis of the interspecies differences in
QTc. It is shown that by applying a correction factor based
on the QT/RR relationships, similar changes in QTc in-
terval are observed between species around the time of the
maximum drug concentration after administration. How-
ever, no precise information on the pharmacokinetics in
the species of interest was available, which precluded a
meaningful analysis of the concentration-effect relation-
ships (10).
By contrast, the PKPD correlation of drug effects on the
QTc interval has been the subject of a number of investi-
gations (11–14). It has been demonstrated that the actual
value of QTc depends on multiple factors related to the
drug and the biological system. Among the numerous
methods developed to account for these complexities, a
Bayesian model has been proposed that constitutes a basis
for identification of drug concentration-effect relationships
(14–16), An important feature of this model is that it en-
ables a separation between drug-specific and biological
system-specific factors (heart rate, circadian rhythm) that
influence the value of the QT interval.
Given the relevance of non-human primates for the
evaluation of the safety profile of biologicals, the aim of
the current investigation was to assess quantitatively the
interspecies differences in the QTc prolonging effects of
moxifloxacin between cynomolgus monkeys, dogs and
humans. This comparison is important because it has been
suggested that monkeys might be the preferred species in
pre-clinical investigations due to similarities to humans in
terms of the magnitude of drug-induced QTc effects (3, 6,
17–19). Data from a new molecule is also presented to
illustrate how the concept can be implemented prospec-
tively during the screening phase.
METHODS
“Retrospective” Evaluation – Reference Compound
(Moxifloxacin)
Experimental Protocols in Cynomolgus Macaques
Blood samples and ECG data were collected in conscious
telemetered cynomolgus macaques according to a 4-way
cross-over design (n=8). Four oral doses ranging between 0
and 90 mg/kg of moxifloxacin were tested, from which the 0
and 90 mg/kg dose group were used for the current investi-
gation. The pharmacokinetics of moxifloxacin in cynomolgus
monkeys was derived from venous blood samples taken at 1, 2,
4, 8 and 24 h post dose. Study design and parameters are
presented in Table IA. The weight range of the monkeys
was 2.8–6.8 kg. Studies were approved by the institutional
Ethics Committee and conducted according to the ethical
standards and GLP procedures.
Experimental Protocols in Dogs and Humans
Details of the experimental protocols for the characterisa-
tion of the pro-arrhythmic effects of moxifloxacin in dogs
and healthy subjects have been published previously
elsewhere (14, 15). Briefly, clinical data for moxifloxacin
were available from the positive control arm of a two-way
crossover, single-blind, randomized, placebo-controlled
Phase I trial in 137 healthy volunteers who received either
placebo or a 400 mg dose. A summary of the relevant
information for the purpose of our investigations is
presented in Table I.
Bioanalysis of Samples from Dogs, Monkeys and Healthy
Volunteers
The determination of moxifloxacin serum concentrations
(Ryan Scientific, Mt. Pleasant, NC, USA) in monkeys was
performed according to the methods described earlier byWat-
son et al. (19). Details on the bioanalysis of moxifloxacin can be
found in Chain and Dubois et al. (14)
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“Prospective” Evaluation - Candidate Molecule
(NCE05)
Experimental Protocol in Cynomolgus Macaques
Blood samples and ECG data were collected in conscious
telemetered cynomolgus macaques. Six monkeys (3 female,
3 male, 2.8–6.8 kg) were treated with four oral doses: 0, 25,
40 and 80mg/kg, of NCE05 fromwhich the first 3 doses were
used in the current investigation. Blood samples for pharma-
cokinetic analysis were collected at 1.5, 4, 8 and 24 h post
dose.
Experimental Protocol in Humans
This was a Phase I, first-time-in-human, randomised, double-
blind, placebo-controlled, parallel group, single centre study
to assess the safety, tolerability, pharmacokinetics and phar-
macodynamic effects of NCE05 following single ascending
doses to healthy volunteers. Four treatment groups were test-
ed with doses of 1, 4, 14 or 30 mg. Study design and popula-
tion details can be found in Table IB. The study has been
conducted in full conformance with the principles of the Dec-
laration of Helsinki and with the local laws and regulations
concerning clinical trials. The protocol and the informed con-
sent documents have been formally approved by the relevant
research Ethics Committees.
Bioanalysis of Samples from Monkeys
Approximately 400 μL blood was collected at each sampling
occasion in lithium heparinised tubes (Microtainer®, Becton
Dickinsson and CO, USA), and cooled on ice. Plasma was
prepared within 30 min by centrifugation (3200 g for 5 min
at +4°C). The plasma was transferred to 1.5 ml MTP system
Topaz PP vial Scantec Lab and immediately frozen at −70°C
until analysis.
Table I Pre-clinical and clinical experimental protocol design and population characteristics for moxifloxacin (A) and NCE05 (B)
A - Moxifloxacin Dog Monkey Healthy subjects
Number of animals/subjects 8 8 137
Gender M M M: 88 (64%)
F: 49 (36%)
Age [yr] – – mean = 27 (18–50)
Dose [mg/kg] 0, 3, 10, 30 0, 90 0, 400
PK sampling times [h] 0, 0.5, 1, 2, 4, 8, 24, 36, 48 0, 1, 2, 4, 8, 24 −1, −0.5, −0.83, 0.25, 0.5, 1, 1.5,
2, 2.5, 3, 4, 6, 8, 10, 12, 24
PD sampling times Every 1 min, averages over 24 h Every 30 s, averages over 24 h −1, −0.5, −0.83, 0.25, 0.5, 1, 1.5,
2, 2.5, 3, 4, 6, 8, 10, 12, 24
PK parameter Plasma concentration Plasma concentration Plasma concentration
Vital signs heart rate, blood pressure, heart rate, blood pressure heart rate
Demographic covariates weight, sex weight, sex weight, sex
ECG parameters LvPr, QT, RR, QRS QT, RR QT, QTcb, QTcf, RR
B - NCE05 Monkey Healthy subjects
Number of animals/subjects 6 24
Gender M M
Age [yr] – –
Dose [mg] 0, 25, 40, 80 1, 4, 14, 30
PK sampling times [h] 0, 1.5, 4, 8, 24 −0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4,
6, 8, 12, 16, 24, 36, 48
PD sampling times [h] −1.17, −1, −0.83, −0.67,
−0.5, 0.5, 1, 2, 3, 4, 6, 8,
12, 16, 20, 24 h
−0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4,
6, 8, 12, 16, 24, 36, 48
PK parameter Plasma concentration Plasma concentration
Vital signs heart rate –
Demographic covariates – weight
ECG parameters QT QT, RR
LvPr left ventricular pressure, QTcb Bazett's corrected QT interval, QTcf Fridericia’s corrected QT interval
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Bioanalysis of Samples from Healthy Volunteers
Blood samples were collected from the forearm using
vacutainer tubes with K2 EDTA. The blood samples were
centrifuged within 30 min from collection for 10 min at 4°C.
The plasma was then frozen at −20°C until analysis. Liquid
chromatography and electro-spray tandemmass spectrometry
(LC-MS/MS) were used to determine the total concentration
of the compound in plasma.
ECG Recordings
Pre-clinical Species
Pre-clinical pharmacodynamic data were collected in con-
scious telemetered animals. Study design and parameters are
summarized in Table IA. ECG recordings were obtained by
implanted radio telemetry devices. Standard aseptic surgical
techniques were used for all implantation procedures. Analysis
of the captured data was made via “Po-Ne-Mah” V4.1 soft-
ware, and/or EMKA “ECG-Auto” version 2.4.0.30.
Clinical Protocol
ECG monitoring was performed with 12-lead electrocardio-
gram, using Marquette ECG machines measuring QT, RR,
and HR. Subjects were kept in a supine position while ECG
recordings were made. Details about clinical study design and
populations characteristics can be found in Table IB.
Data Analysis
Pharmacokinetic (PK) Data
Pharmacokinetic modelling and deconvolution techniques
were used for imputation and interpolation of concentrations
at the ECG assessment times. In brief, analysis of the pharma-
cokinetic data from the clinical and in vivo dog study with
moxifloxacin was performed using non-linear mixed effects
modelling techniques in NONMEM 6.0 and 7.1.2 (ICON,
Maryland, USA), respectively. By contrast, a deconvolution
method (WINNONLIN v4.1, Pharsight, USA) was used for
the estimation of individual concentrations for NCE05 and
moxifloxacin in cynomolgus monkeys. This method was used
as no satisfactory individual prediction results could be obtain-
ed by modelling of the data in this species. The use of
deconvolution is considered an acceptable approach for inter-
polation of the concentration data at time points between the
available blood sampling times (20).
It should be noted that for the purpose of the current
analysis, samples below the lower limit of quantification were
set to zero. In addition, to prevent numerical difficulties
during parameter estimation, all drug concentrations of the
1 mg study group for NCE05 were also set to zero. Model
characteristics and parameters describing moxifloxacin
pharmacokinetics are summarised in Table II.
Pharmacokinetic-Pharmacodynamic (PKPD) Modelling
Model building was performed inWinBUGS version 1.4.2, as
previously described in Chain and Dubois et al. (14, 16). In brief,
the PKPD model comprises three components, which are es-
timated simultaneously during the fitting procedures: an indi-
vidual correction factor for RR-interval, an oscillatory func-
tion describing the circadian variation of the baseline QTc
values and a linear function to capture the concentration-
effect relationship (15). These components are summarised
in Eq. 1:
Q T ¼ Q T C0⋅RRα þ A⋅cos 2π24 t−ϕð Þ
 
þ slope⋅C ð1Þ
where QTc0 [ms] is the individually corrected baseline QTc,
RR [ms] is the interval between successive R waves, α is
the individual heart rate correction factor, A [ms] is the
amplitude of circadian rhythm, t is the clock time, φ is the
phase, slope [ms/nM] is the linear concentration-effect
relationship, and C is the concentration of drug at the
time of QT measurements.
This type of parameterisation allows one to distinguish be-
tween system- and drug specific properties. Consequently,
these parameters can be used to compare drug properties
across species without the need for further correction factors.
While the same model was used for the description of QT-
intervals for both compounds and both species, each analysis
was conducted independently. Since ECG recordings in dogs
and monkeys were performed in a continuous manner, data
filtering was applied to ensure data sets of workable sizes were
used in the joint analysis with clinical data. Data filtering was
performed taking into account the absorption and disposition
profiles for the different species, so that absorption, peak and
elimination phases were accurately and equally represented in
a balanced dataset.
The R package R2WinBUGS was used to execute
WinBUGS whilst running a session in R 2.12.8 (21). Conver-
gence was assessed visually by monitoring the dynamic traces
of Gibbs iterations and by computing the Gelman-Rubin,
Geweke, Raftery-Lewis and Heidelberger-Welch test statistics
for all model parameters (22–24). All PKPD parameter esti-
mates were obtained as posterior distributions.
Probability of QT Interval Prolongation
A threshold of 10 ms QTc prolongation at pre-defined con-
centrations was selected as a measure for comparison of drug
effect across species. The magnitude of this threshold was
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based on the assumption that if differences in sensitivity exist
between species, one can easily interpret the potential impli-
cations of pro-arrhythmic activity in humans. The analysis was
performed using the slope and the inter-individual correction
factor for gender together with a step function in WinBUGS
1.4 (see Eq. 2) at arbitrary concentration values in such a way
that data points cover the complete sigmoid curve.
P≥10ms at Cð Þ ¼ step 0:00001F Genderð Þ⋅slope⋅ 10ms
C
 
ð2Þ
where 0.00001 is set as an arbitrary small number to avoid
computational errors, 10 ms is the QT interval prolongation
threshold of interest, C is the drug concentration, and slope is
the QT increase per unit drug concentration.
Probability curves were plotted for each compound. Sub-
sequently, the concentration at which the probability of QT
prolongation ≥10 ms is 0.5 (Cp50) was determined by linear
regression. The safety margin, as defined by the ratio between
Cp50 and peak concentration (Cp50/Cmax), was then estimat-
ed for each compound.
RESULTS
Pharmacokinetics
As described previously in the methods, drug concentrations
at the time of ECG measurement were imputed or interpo-
lated either by population pharmacokinetic modelling or
deconvolution, depending on which technique provided the
best description of the data, minimising the impact of uncer-
tainty and poor precision in individual predicted concentra-
tions on the PKPD analysis. Observed (time-matched),
interpolated or otherwise predicted concentrations were de-
rived at the time of the QT measurements and subsequently
used for the PKPD analysis. The pharmacokinetic parameter
estimates for moxifloxacin are summarised in Table III. Mod-
el predictions and goodness-of-fit plots are depicted in Figs. 1
and 2 for moxifloxacin and NCE05, respectively.
PKPD Modelling
The recorded ECG measurements were used for modelling
purposes in conjunction with the predicted (or interpolat-
ed) drug concentrations. Diagnostic criteria and goodness-
of-fit plots showed comparable model performance in all
three species (Figs. 3 and 4). System specific parameters
(baseline QTc (QTc0), QT-RR exponential correction fac-
tor (α), amplitude (A) and phase (Ф)) showed values within
the same range for both drugs within dogs and monkeys.
The main difference between species and compounds was
found in the drug specific parameter (i.e., slope) (Table IV).
The QT-RR correc t ion fac tor (α ) ob ta ined for
Table II Moxifloxacin pharmacokinetic model characteristics
Moxifloxacin Dogs Monkeys Healthy subjects
PK model diagram
Vc
Cl
Ka
N/A
Vc VpQ
D1, Ka
Cl
Parameters Ka, Vc, CL, F* N/A D1, Ka, CL, Vc, Vp, Q
BSV CL D1, Ka, CL, Vc, Vp, Q
Covariates N/A N/A
Derived PK time points 1–2 h: every 2 min,
2–10 h: every 5 mins
10–47 h every 15 mins
time–matched samples 1–2 h: every 2 min,
2–10 h: every 5 mins
10–47 h every 15 mins
BSV between-subject variability, CL apparent oral clearance, D1 parameter describing zero-order absorption duration process, Ka absorption rate constant,
Q intercompartmental clearance, Vc volume of distribution of the central compartment, Vp volume of distribution of the peripheral compartment
*F bioavailability, estimated separately per dose level
Table III Moxifloxacin pharmacokinetic population parameter estimates
Dogs Healthy subjects
Parameter mean IIV% mean IIV%
Ka [/h] 1.78 – 2.21 88.65
D1 [h] – – 0.629 85.14
CL [L/h] 3.39 21 13.4 12.69
Vc [L] 43.23 – 122 28.77
Vp [L] – – 55.4 44.27
Q [L/h] – – 78.4 –
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moxifloxacin and NCE05 varied significantly in humans.
On the other hand, in contrast to moxifloxacin, the slope of
NCE05 was not significantly different from zero, nor was
there an increase in QT across the observed concentration
range.
Interspecies Comparison
The use of animal models for the prediction of drug effects in
humans requires the identification of system specific proper-
ties. Therefore, the choice of model parameterisation is criti-
cal, in that it should allow the distinction between system-
specific parameters, and drug-specific parameters and their
respective variability. Despite the limited evidence from two
compounds, our analysis shows similar estimates of the
system-specific physiological parameters in each species. By
contrast, the values of these parameters differed significantly
between the species.
The availability of a common model to describe drug
effects across species in a parametric manner offers impor-
tant advantages from a drug development perspective.
Figure 5 summarises the goodness-of-fit plots and the
curves describing the relation between the drug concentra-
tion and the probability of a QT interval prolongation
≥10 ms. As it can be seen from the three probability curves
for moxifloxacin, there is a clear shift in the PKPD
relationship between preclinical species and humans, with
lower values of the Cp50 in dogs and monkeys. In addition,
it appears that the slope (i.e., the drug specific parameter)
of the relationship between drug concentration and QT
interval prolongation also differs between the species for
each drug.
Our attempt to illustrate the use of the approach for
prospective evaluation of novel compounds showed that
the magnitude of the changes in parameter estimates may
not be systematic, i.e., a higher slope parameter was
observed in monkeys following administration of NCE05,
Fig. 1 Predicted and observed pharmacokinetic profiles of moxifloxacin after administration of different dose levels to dogs (left panels), monkeys (mid panels) and
humans (right panels). The upper panels show examples of the individually predicted concentrations. Mid panels: observed (symbols) and population predicted
(lines) concentrations. Lower panels: goodness-of-fit plots depicting the observed vs predicted concentrations (symbols). The solid line represents the identity line
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as compared to humans. The Cp50 values derived from the
probability curves were 6469 vs 2597 nM for moxifloxacin
and 449 vs 2910 nM for NCE05 in monkeys and humans,
respectively. Based on these estimates, safety margins
(Cp50/Cmax ) were found to be 0.62 v s 0.25 for
moxifloxacin and 4.5 vs 29.1 for NCE05 in monkeys and
humans, respectively.
DISCUSSION AND CONCLUSIONS
Our findings show that a model-based approach can be used to
quantitatively assess interspecies differences in the QT
prolonging effect of moxifloxacin, confirming the feasibility of
the approach in a second non-clinical species after our first results
comparing drug effects in dogs and humans. From a drug devel-
opment perspective, the availability of a general PKPD model
enables the evaluation of the pharmacological (QT interval
prolonging) effect in humans, taking into account clinically rele-
vant exposure ranges. Using a reference compound and novel
candidatemolecule and explicit distinction between drug-specific
and system-specific parameters, our results suggest that intrinsic
differences exist in the PKPD relationships in dogs andmonkeys,
which make the direct extrapolation or translation of drug effects
from these pre-clinical animal species humans rather challenging.
PKPD Modelling
Despite the increased understanding of PKPD relationships and
the role of modelling and simulation in drug development, pro-
spective use of PKPD models as a predictive tool for the evalua-
tion of drug safety has been limited (25). This is partly explained
bymodel building requirements, which are often time-consuming
and impose appropriate experimental design and dose rationale.
One important feature of our analysis was therefore to illustrate
how PKPD relationships in pre-clinical species can be used to
identify potential differences between animals and humans.
As shown in Fig. 5, the modular structure of the model,
including systems- and drug-specific parameters allowed direct
comparison of drug-induced effects across species. In fact, our
results for moxifloxacin indicate that drug-induced QT
prolonging effects occur at different exposure ranges in dogs,
monkeys and humans. These data can be integrated, as illustrat-
ed here, to estimate the probability of QT interval prolongation
≥10ms. Contrary to prevailing views about the sensitivity of pre-
clinical species to detect safety signals, the probability curve in
humans clearly shows a steeper increase across the therapeutic
concentration range of each compound, indicating the risk of
QT prolongation ≥10 ms at such levels. In contrast, the maxi-
mum probability of QT prolongation occurs at higher exposure
in dogs and monkeys than in humans, suggesting differences in
the sensitivity to the QT-prolonging effects across species.
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Fig. 2 (Upper panels) Examples of
individually predicted
concentrations of NCE05. Lower
panels depict the observed (symbols)
and mean predicted (lines)
concentrations in monkeys and
humans. Pre-clinical doses ranged
from 25 mg/kg (dashed line/△) to
40 mg/kg (dotted line/+), whereas
healthy subjects received doses of
4 mg (dashed line/△), 14 mg (dotted
line/+) or 30 mg (dash dotted line/
×)
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Fig. 3 Model performance and predicted QT profiles after administration of placebo and different doses of moxifloxacin to dogs (left panels), cynomolgus monkeys
(mid panels) and humans (right panels). Observations are indicated by symbols, population predictions by lines. The solid line in the lower panels represents the identity
line. In dogs: ○ (grey) and _____ are pre–dose values; △ (yellow) and _ _ _ _ are placebo; + (greenish) and - - - - 3 mg/kg, x(slate grey) and - _ - _ 10 mg; ◊(light blue)
and __ __ __ 30 mg. In monkeys: × (black)/solid line are placebo; * (red)/dashed line 90 mg/kg. In humans: dashed line and symbols depict effects of a 400 mg dose
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Fig. 4 Model performance and
predicted QT profiles after
administration of placebo and
different doses of NCE05 to
cynomolgus monkeys (left panels)
and healthy subjects (right panels).
Observations are indicated by
symbols, population predictions by
lines. The solid line in the lower
panels represents the identity line. In
monkeys: * (green)/solid line are
placebo; △ (red)/dashed line
25 mg/kg; + (blue)/dotted line
40 mg/kg. In humans: * (green)/solid
line 1 mg; △ (red)/dashed line 4 mg;
+ (blue)/dotted line 14 mg; ×
(black)/dashed-dotted line 30 mg
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Experimental Protocols for Drug Screening
Despite the wide number of experimental protocols for in vivo
screening, uncertainty exists about which species and
experimental conditions bear clinical relevance and hence
can be used as basis for decision-making. Clearly, any attempt
to translate pre-clinical findings must account for the impact
of experimental procedures on the measures and parameters
Table IV PKPD parameter estimates and 95% credible intervals obtained for moxifloxacin and NCE05
Moxifloxacin NCE05
Dogs (n=8) Monkeys (n=8) Healthy subjects (n=24) Monkeys (n=6) Healthy subjects (n=24)
QTc0 [ms] 240 (238–242) 341 (337–347) 399 (394–403) 367 (349–390) 378 (373–383)
Sex effect [ms] N/A N/A 8 (5–12) N/A N/A
α 0.28 (0.22–0.35) 0.48 (0.36–0.64) 0.40 (0.38–0.42) 0.55 (0.50–0.60) 0.26 (0.23–0.31)
A [ms] 4.6 (3.1–7.0) 14.9 (10.1–22.3) 2.4 (1.7–2.9) 7.6 (2.6–21) 4.2 (2.6–5.8)
φ [h] 23.1 (15.1–34.6) 24.9 (20.6–30.2) 10.0 (7.3–12.9) 24 (20–29) 8.1 (5.2–11)
Slope [ms/nM] 0.00056
(0.00002–0.0014)
0.0016
(0.0008–0.0026)
0.0039
(0.0033–0.0044)
0.022
(0.0097–0.041)
0.0052
(−0.0048–0.016)
BSV (QT0) % 6.46 (6.43–6.48) 5.41 (5.37–5.45) 5.01 (4.98–5.04) 5.2 (5.1–5.2) 5.2 (5.1–5.2)
BSV (α) % 86 (48–177) 51 (27–110) 41 (33–52) 1.9 (1.0–4.4) 19 (13–29)
BSV (A) % 9.8 (7.4–14.8) 10.4 (8.1–15.2) 5.3 (3.6–8.0) 2.6 (1.6–5.2) 8.2 (5.0–14)
BSV (φ) % 13 (8–23) 6.2 (4.1–10.3) 18 (10–31) 3.2 (1.6–7.9) 16 (8.1–34)
BSV (Slope) % 25 (17–39) 36 (25–58) 41 (29–53) 42 (23–99) 37 (21–87)
Residual Error [ms] 9.4 (9.3–9.5) 10.0 (9.8–10.3) 5.3 (5.2–5.4) 7.4 (6.8–8.1) 16 (13–19)
Prob ≥10 ms at Cmax 1.0 1.0 1.0 1.0 0
Cmax [nM] 112,930 31,400 10,300 8660 101
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Fig. 5 (Upper panel) Observed vs
model predicted QT interval for
moxifloxacin (left) and NCE05
(right). Black circles, grey crosses and
slate grey triangles represent the
experimental observations in dogs,
cynomolgus monkeys and humans,
respectively. (Lower panel)
Comparison of the risk of drug-
induced QTc prolongation across
species. Dotted line: calculated
values for conscious dogs; dashed
grey line: calculated values for
monkeys; solid, black line: calculated
values for humans. The thick black
line indicates the observed Cmax
range of the clinical study
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of interest (26). Consequently, the lack of attention to clinically
relevant aspects in safety pharmacology experiments is prob-
ably one of the major hurdles in identifying interspecies cor-
relations or scaling functions.
The first element worth mentioning is the target exposure
range in preclinical protocols and the expected therapeutic
and supra-therapeutic levels in humans. Clearly, interspecies
differences in drug disposition, metabolism and bioavailability
need to be factored in to ensure appropriate levels are reached
and to enable an unambiguous interpretation of the results.
The available protocols rely on empirical choices for the dose
selection. For instance, moxifloxacin peak concentrations
differed only three fold between monkeys and humans, whilst
an 86-fold difference was observed for the new molecule
NCE05. Such a difference in exposure impairs the comparison
of PKPD relationships, as overexposure of such a magnitude
may lead to other adverse events, which in turn can mask the
primary pharmacological (QT prolonging) effects. In addition,
multiple interactions may occur, with potentially antagonising
effects if the compound under investigation shows affinity for
more than one specific ion channel (27, 28). Extrinsic sources
of variability may also contribute to noise. Food intake (usually
at 4 h post dose) in pre-clinical protocols can greatly affect QT
interval, which will decrease irrespective of drug levels, as can be
seen in the moxifloxacin data (Fig. 3). The correction for RR
differences does reduce most of the food-induced QT decrease,
but residual differences may mask the intrinsic effects of
candidate molecules which cause small prolongation (29, 30).
Another important design aspect is the use of informative
sampling schemes, with sampling intervals and frequencies that
allow correct characterisation of the pharmacokinetics. For
instance, the standard experimental design used for NCE05
had important limitations, as samples were lacking in the first
1.5 h post dose, a period during which the absorption process
occurs and where consequently the highest peak concentrations
might have occurred. Absence of such information impairs the
estimation of peak levels and possibly maximum drug effects.
Translational Pharmacology
As a comparison of the parameter estimates with published
literature data is not possible, it appears from the present inves-
tigation that dogs are less sensitive than monkeys and monkeys
slightly less sensitive than humans to the QT-prolonging effects
of moxifloxacin. This can be seen by the difference in the slope
parameter of the concentration-effect relationship and the
difference in the probability of reaching ≥10 ms increase in
QTc interval at exposure levels corresponding to the approved
therapeutic doses. More specifically, for moxifloxacin the differ-
ences in the slopes of the linear concentration-effect relations
between monkeys (0.0016 ms/nM) and humans (0.0039 ms/
nM) is smaller than in dogs (0.00056) (14). As these results are all
obtained with the same model, they can be compared reliably.
On the other hand, it is well known that concentration-effect
relationships can differ between species, as result of for example
differences in homeostatic processes, circadian variation, target
expression and/or transduction mechanisms (31–34). Such dif-
ferences need to be taken into account in the extrapolation of
drug effects from pre-clinical species to humans, possibly by
means of a system-specific translation function (34–36). In fact,
the topic of interspecies scaling of drug-induced QTc interval
prolongation was recently addressed in an extensive investiga-
tion byHolzgrefe et al. (9). Their work however has not considered
the role of pharmacokinetics and therefore a detailed andmean-
ingful analysis of the PKPD relationship over a wide concentra-
tion range was not possible. Specifically, a concentration-effect
correlation was estimated by assuming a dose scaling factor and
using the data obtained in a 1-h time interval around the Tmax,
i.e., an empirical approach which disregards the differences in
the pharmacokinetic profile of different compounds (14, 37).
From a drug development perspective our approach offers
the opportunity to use modelling and simulation for the pro-
spective evaluation of novel compounds (38). By contrast, re-
cent examples of the analysis of QTc interval data fail to
create a direct, quantitative correlation between clinical data
and pre-clinical findings. In cases where this was attempted,
additional in vitro data was needed in order to identify a plau-
sible correlation between species (13, 39). A limiting factor in
these analyses is that the model cannot be reused for any other
compound or compound class. This rather undermines the
intended utility of such models; namely to support the screen-
ing of compounds in the early stages of drug development.
Limitations
We have made assumptions about the data sets available from
the trials and experimental protocols. Firstly, we have assumed
that monkey data from the top dose yielded information on the
clinically relevant exposure levels of moxifloxacin, whereas the
placebo arm was sufficient to capture the natural variation in
baseline and system-specific parameters. The data from interme-
diate dose levels was found to be unsuitable for modelling
purposes.
In the data available from the clinical trial with NCE05,
details on baseline assessment day were missing. However, a
very low dose was administered (1 mg) to healthy subjects in
one of the arms, which resulted in very low concentrations,
close to the LLOQ. In order to strengthen the estimation of
the system specific parameters, it was decided to set the drug
concentrations to zero for all assessment times and treat this
arm as the baseline (placebo) data.
We have also made assumptions about the low probability
of describing drug effects based on a traditional Emax model,
given that a hyperbolic function may not be observable in vivo
due to arrhythmias in pre-clinical species and in humans. In
addition, in clinical trials subjects are withdrawn from the
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trials if ECG stopping criteria are reached (e.g. QTc >
500 ms). Considering these factors, estimation of a maximum
effect may be difficult and a small misspecification of this pa-
rameter could lead to a considerable bias in the estimation of
the potency parameter, IC50. As a 10 ms increase in the QT
interval can increase the risk on TdP significantly, bias in IC50
estimates can lead to false positive or false negative results and
wrong conclusions about the pro-arrhythmic risk. A linear
concentration-effect relationship was therefore deemed to re-
flect the lower end of the ascending portion of a theoretical
Emax curve. It should be noted that whilst the use of the Emax
model has been shown to result in some improvement in terms
of the precision of parameter estimates and residual variability
(12, 40, 41), other examples are also available where a linear
effect model showed better performance (42, 43).
Another important point is the assumption that NCE05
shares the same pro-arrhythmic mechanisms at low and high
exposure levels. The exclusion of the high dose level from the
analysis was based on the clinical relevance of concentration
range observed in the lower dose groups. Furthermore, it
should be noted that one cannot exclude the role of sample
size as a determinant of the wide credible intervals for drug-
specific parameters Uncertainty in parameter estimates may
be partly explained by the limited data available in the ther-
apeutic concentration range.
Quantitative data are lacking to allow a somewhat mecha-
nistic explanation of the observed difference in drug sensitiv-
ities and system specific parameters in dogs and monkeys.
Although our model can be used to characterise interspecies
differences in drug sensitivity, the contribution of multiple
underlying mechanism of QTc prolongation should not be
overlooked. Compounds with variable degree of affinity for
different ion channels will behave differently across species
depending on the expression level and overall tissue density
of the each channel (sub) type.
Lastly, we should emphasise the implications of poor quality
data on drug disposition properties. Inadequate dose rationale or
sub-optimal blood sampling schemes can lead to model
misspecification, bias and poor precision in PK and PKPD pa-
rameter estimates. Such poor experimental conditions will have
direct impact on the drug-specific parameter (i.e., the slope in
Eq. 1), defeating the objectives of quantitative PKPDmodelling.
In summary, the use of a model-based approach has en-
abled the assessment of the interspecies differences in the
concentration-QT prolonging effect relationship of
moxifloxacin. These differences are reflected by the probabil-
ity threshold for QT interval prolongation ≥10 ms, which was
found to differ between species. Irrespective of the intrinsic
differences in cardiac function between dogs, monkeys and
humans, our approach shows that accurate evaluation of the
pro-arrhythmic potential of a novel compound cannot be per-
formed without disentangling drug-specific parameters from
system-specific parameters.
The current results also suggest that different experimental
protocols may be required, including potentially larger sample
sizes in dogs as monkeys to allow estimation of model param-
eters with sufficient precision. The observed lower sensitivity
of dogs to the effects of moxifloxacin, as compared to monkeys
has been suggested previously and seems to be supported by
this initial analysis. Further investigation using multiple com-
pounds with known arrhythmogenic properties is needed to
assess whether the observed differences across species are
systematic.
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